New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy
Oct. 17, 2016
| By Bill Briggs / Fred Hutch News Service
Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.
Applicants wanted for most inclusive fellowship program among top cancer centers; Dr. Oliver Press honored as new Giuliani/Press Endowed Chair; possible new path to targeted therapies for certain leukemias, myelodysplastic syndrome.
Notable accomplishments: Dr. Hans-Peter Kiem and colleagues explore new source of stem cells and gene therapy; Dr. Justin Taylor publishes a paper describing the path or paths individual naive B cells can take to maturity; Graduate student Nitobe London among 2015 Weintraub award winners
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.